

**Exhibit B**

```

<!--StartFragment-->RESULT 2
AAB42635
ID   AAB42635 standard; protein; 401 AA.
XX
AC   AAB42635;
XX
DT   08-FEB-2001 (first entry)
XX
DE   Human ORFX ORF2399 polypeptide sequence SEQ ID NO:4798.
XX
KW   Human; open reading frame; ORFX; detection; cytostatic; hepatotropic;
KW   vulnerary; antipsoriatic; antiparkinsonian; nootropic; neuroprotective;
KW   anticonvulsant; osteopathic; antiarthritic; immunosuppressant; cardiant;
KW   immunostimulant; thrombolytic; coagulant; vasotropic; antidiabetic;
KW   hypotensive; dermatological; immunosuppressive; antiinflammatory;
KW   antiviral; antibacterial; antifungal; antirheumatic; antithyroid;
KW   antianaemic; gene therapy; cancer; proliferative disorder; hypertension;
KW   neurodegenerative disorder; osteoarthritis; graft vs host disease;
KW   cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;
KW   cholesterol ester storage; systemic lupus erythematosus; infection;
KW   severe combined immunodeficiency; malaria; autoimmune disorder; asthma;
KW   allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;
KW   bone damage; cartilage damage; antiinflammatory disease; coagulation;
KW   thrombosis; contraceptive.
XX
OS   Homo sapiens.
XX
PN   WO200058473-A2.
XX
PD   05-OCT-2000.
XX
PF   31-MAR-2000; 2000WO-US008621.
XX
PR   31-MAR-1999; 99US-0127607P.
PR   02-APR-1999; 99US-0127636P.
PR   05-APR-1999; 99US-0127728P.
PR   30-MAR-2000; 2000US-00540763.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Shimkets RA, Leach M;
XX
DR   WPI; 2000-602362/57.
DR   N-PSDB; AAC76844.
XX
PT   Novel nucleic acids and peptides derived from open reading frame X,
PT   useful for treating e.g. cancers, proliferative disorders,
PT   neurodegenerative disorders and cardiovascular disease.
XX
PS   Claim 11; Page 3982-3983; 5507pp; English.
XX
CC   AAC74446 to AAC77606 encode the proteins given in AAB40237 to AAB43397,
CC   which represent the human ORFX open reading frames 1 to 3161. The ORFX
CC   sequences have activities such as: cytostatic; hepatotropic; vulnerary;
CC   antipsoriatic; antiparkinsonian; nootropic; neuroprotective; osteopathic;
CC   anticonvulsant; antiarthritic; immunosuppressant; immunostimulant;
CC   cardiant; thrombolytic; coagulant; vasotropic; antidiabetic; hypotensive;
CC   dermatological; immunosuppressive; antiinflammatory; antibacterial;
CC   antiviral; antifungal; antirheumatic; antithyroid; and antianaemic. The
CC   sequences can be used for determining the presence of or predisposition
CC   to, or preventing or treating pathological conditions associated with an
CC   ORFX-associated disorder. The nucleic acids can be used to express ORFX
CC   proteins in gene therapy vectors. The proteins and nucleic acids may be
CC   used to treat cancers, proliferative disorders, neurodegenerative
CC   disorders, osteoarthritis, graft vs host disease, cardiovascular disease,
CC   diabetes mellitus, hypertension, hypothyroidism, cholesterol ester
CC   storage, systemic lupus erythematosus, severe combined immunodeficiency
CC   (SCID), AIDS, viral, bacterial or fungal infection, malaria, autoimmune
CC   disorders, asthma, allergies, aplastic anaemia, burns, wounds, bone and
CC   cartilage damage, nocturnal haemoglobinuria, antiinflammatory disease; to
CC   enhance coagulation; to inhibit thrombosis; and as a contraceptive
XX
SQ   Sequence 401 AA;

Query Match      100.0%; Score 1784; DB 3; Length 401;
Best Local Similarity 100.0%; Pred. No. 2.5e-141;

```

Matches 349; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTIGEMLRSLTKLEWFSTLFPRIQKIDQIKTRPRKIKKDGKEGAEIDRHVER 60  
|||||

Db 53 MTIGEMLRSLTKLEWFSTLFPRIQKIDQIKTRPRKIKKDGKEGAEIDRHVER 112

Qy 61 RRSRSPRRSLSPRRSPRRSRSHHREGHGSSSFDRELEREKERQRLEREAKEREKERR 120  
|||||

Db 113 RRSRSPRRSLSPRRSPRRSRSHHREGHGSSSFDRELEREKERQRLEREAKEREKERR 172

Qy 121 SRSIDRGLERRRSRERHRSRSDRKGDRDRDREREKENERGRRDRDYDKERGNE 180  
|||||

Db 173 SRSIDRGLERRRSRERHRSRSDRKGDRDRDREREKENERGRRDRDYDKERGNE 232

Qy 181 REKERERSRERSKEQSRGGEVEEKKHKEDKDDRRHRDDKRDSSKEKKHSRERSRERKHRS 240  
|||||

Db 233 REKERERSRERSKEQSRGGEVEEKKHKEDKDDRRHRDDKRDSSKEKKHSRERSRERKHRS 292

Qy 241 RSRSRNAGKRSRERSKEKSSKHKNESKEKSNKRSRSGSQGRDTSVEKSKKREHSPSKEKS 300  
|||||

Db 293 RSRSRNAGKRSRERSKEKSSKHKNESKEKSNKRSRSGSQGRDTSVEKSKKREHSPSKEKS 352

Qy 301 RKRSRSKERSHHRDHSKQSDKHDRRRSQSIEQESQEKQHKNKDETV 349  
|||||

Db 353 RKRSRSKERSHHRDHSKQSDKHDRRRSQSIEQESQEKQHKNKDETV 401

<!--EndFragment-->